Al­ny­lam makes RNAi his­to­ry again as patisir­an gets ap­proved in Eu­rope; Ver­tex buys in­to UK-based ma­chine learn­ing ...

7 years ago
News Briefing

Bay­er gets green light to sell long-act­ing he­mo­phil­ia A ther­a­py as Roche mus­cles in with Hem­li­bra

7 years ago
Pharma

Pfiz­er ax­es a key Duchenne MD pro­gram af­ter PhII flop, rais­ing new doubts for a drug cat­e­go­ry that at­tract­ed Roche ...

7 years ago
R&D

An elite team of young, transpa­cif­ic sci­en­tists out of Har­vard and MIT starts plow­ing next-gen cell ther­a­py tech ...

7 years ago
Startups

Close­ly al­lied with (both) Mer­cks and Cel­gene, Sutro CEO Bill Newell is lay­ing out all his cards in a new IPO

7 years ago
Financing

FDA launch­es pi­lot pro­gram in sup­port of com­plex tri­al de­signs for drugs and bi­o­log­ics

7 years ago
Pharma

Am­gen vet Lau­ra Hamill takes com­mer­cial reins at Gilead amid ex­ec­u­tive shake­up

7 years ago
People

A faster treat­ment for tu­ber­cu­lo­sis? TB Al­liance launch­es piv­otal tri­al for four-drug reg­i­men

7 years ago
R&D
Discovery

Emer­gent snags opi­oid drug in $735M buy­out deal; Ger­many frets about post-Brex­it dis­rup­tion in drug mar­ket

7 years ago
News Briefing

Pop­u­lar biotech boost­ers get­ting mul­ti­mil­lion-dol­lar pay­outs on Wall Street as top an­a­lysts are wooed with big of­fers ...

7 years ago
Pharma

A for­mer fail­ure in PhII, the go-go FDA says it’s ready to con­sid­er an ac­cel­er­at­ed short­cut for Ul­tragenyx's UX007

7 years ago
R&D

Pfiz­er bris­tles at 'mis­lead­ing' com­ments from Big Phar­ma ri­vals Am­gen, Genen­tech on biosim­i­lars

7 years ago
Pharma

Sophiris says it’s ready to get back on track with lead drug af­ter pa­tient death — but ques­tions linger

7 years ago
R&D

As the maid­en biotech IPO on the HKEX fiz­zles, some in­vest­ment ex­perts see an up­side in tem­per­ing the hype

7 years ago
Financing
China

The boom­ing Boston/Cam­bridge biotech hub claims an in­dus­try-lead­ing role — no­body beats it at rais­ing record ...

7 years ago
Pharma

GSK spin­out KaNDy rais­es $32M to fund a break­through shot at a wom­en's health drug

7 years ago
Financing
Startups

Are­na's di­et drug castoff deemed safe in study; UK price over­seers say break­through CAR-T Yescar­ta is too ex­pen­sive

7 years ago
News Briefing

Tetraphase plots Q4 launch for first an­tibi­ot­ic af­ter long-await­ed OK for er­ava­cy­cline

7 years ago
Pharma

Bris­tol-My­ers pro­motes a com­mer­cial play­er to top sales job — re­plac­ing new Am­gen ex­ec Mur­do Gor­don

7 years ago
People

Alzheon IPO take two: Will in­vestors back a down­sized of­fer­ing from an Alzheimer’s biotech?

7 years ago
Financing

Vivek Ra­maswamy bags $100M in risk cap­i­tal to back his lat­est PhI­II gam­ble at Der­ma­vant — while Urovant dives in­to ...

7 years ago
People
Financing

Io­n­is, Akcea just got hand­ed a one-way tick­et to the end of the reg­u­la­to­ry line as the FDA re­jects volane­sors­en

7 years ago
Pharma

The new Cin­derel­la sto­ry: Can­cer pow­er­house Genen­tech lines up an NK al­liance with Af­fimed loaded with bil­lions in ...

7 years ago
Pharma

No­var­tis qui­et­ly hands top­i­cal treat­ment for rare dis­ease to Life­Max — lat­est in a string of out-li­cens­ing deals

7 years ago
R&D
Pharma
First page Previous page 1014101510161017101810191020 Next page Last page
A service from the Financial Times